Top

Published in:

01-04-2018 | Original Article

The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients

Authors: Shunsuke Kiuchi, Shinji Hisatake, Takayuki Kabuki, Takashi Oka, Shintaro Dobashi, Takahiro Fujii, Takanori Ikeda

Published in: Heart and Vessels | Issue 4/2018

Abstract

The effect of early use of tolvaptan (TLV) for acute decompensated heart failure (ADHF) is unclear. We investigated the relationship between early use of TLV and the length of hospital stay. 369 consecutive ADHF patients who received TLV during hospitalization between February 2011 and June 2016 were initially enrolled. Patients who died in hospital, transferred hospital or clinical scenario 4 or 5 were excluded. We analyzed 247 ADHF patients. We evaluated the relationship between the length of hospital stay and the following findings: blood pressures, heart rate, New York Heart Association classification, and blood tests on admission. Moreover, we also evaluated treated agents and TLV initiated days from admission. TLV initiated days was statistically associated with the length of hospital stay (r = 0.625, P < 0.001). We compared the early use (within 4 days) vs delayed use of TLV (5 days or later), because the median of time until commencement of TLV from hospitalization was 4 days. The length of hospital stay in the delayed use group was significantly longer than early use group (31.9 ± 20.4 and 21.0 ± 12.9 days, P < 0.001). However, there was no difference in the length of hospital stay after initiation of TLV in both groups. Moreover, we investigated the factors related to the long-term hospitalization (hospital stay of median length or more). Multivariate analysis showed that TLV initiated days was independently related to the long-term hospitalization (odds ratio 1.32, 95% confidence interval 1.13–1.53, P < 0.001). Early use of TLV was related to the length of hospital stay for ADHF patients.

Matsuzaki M, Hori M, Izumi T, Fukunami M (2011) Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 25(Suppl 1):S33–S45CrossRefPubMed

Uemura Y, Shibata R, Takemoto K, Uchikawa T, Koyasu M, Ishikawa S, Mitsuda T, Miura A, Imai R, Iwamiya S, Ozaki Y, Kato T, Miura T, Watarai M, Murohara T (2016) Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease. Heart Vessels 31:1643–1649CrossRefPubMed

Imamura T, Kinugawa K (2016) Tolvaptan improves the long-term prognosis in patients with congestive heart failure with preserved ejection fraction as well as in those with reduced ejection fraction. Int Heart J 57:600–606CrossRefPubMed

Hanatani A, Shibata A, Kitada R, Iwata S, Matsumura Y, Doi A, Sugioka K, Takagi M, Yoshiyama M (2017) Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction. Heart Vessels 32:287–294CrossRefPubMed

Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C (2007) Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. the EVEREST outcome trial. JAMA 297:1319–1331CrossRefPubMed

Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O’Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA (2007) Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 49:2151–2159CrossRefPubMed

Nishi I, Seo Y, Hamada-Harimura Y, Sato K, Sai S, Yamamoto M, Ishizu T, Sugano A, Obara K, Wu L, Suzuki S, Koike A, Aonuma K (2017) Ibaraki Cardiovascular Assessment Study-Heart Failure Investigators. Nutritional screening based on the controlling nutritional status (CONUT) score at the time of admission is useful for long-term prognostic prediction in patients with heart failure requiring hospitalization. Heart Vessels 32:1337–1349CrossRefPubMed

Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, Ono Y, Fujii H, Kitai T, Nishioka T, Sugi K, Onishi Y, Noda M, Kagiyama N, Satoh Y, Yoshida K, van der Meer P, Damman K, Voors AA, Goldsmith SR (2017) Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clin Res Cardiol. doi:10.1007/s00392-017-1122-1 PubMedPubMedCentral

Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, Izawa A, Ikeda U (2016) Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol 67:399–405CrossRefPubMed

10.

McKee PA, Castelli WP, McNakamura PM, Kannel WB (1971) The natural history of congestive heart failure: the Framingham study. N Eng J Med. 285:1441–1446CrossRef

11.

Matsukawa R, Kubota T, Okabe M, Yamamoto Y, Meno H (2017) Efficacy and safety of the early use of V2 receptor antagonists in elderly patients with decompensated heart failure. Heart Vessels. doi:10.1007/s00380-017-1039-7 PubMed

12.

Fukui M, Tsujino T, Hirotani S, Ito H, Yamamoto K, Akasaka T, Hirano Y, Ohte N, Daimon T, Nakatani S, Kawabata M, Masuyama T (2017) Changes in brain natriuretic peptide in chronic heart failure patients treated with long-acting versus short-acting loop diuretics: J-MELODIC subanalysis. Heart Vessels 32:865–871CrossRefPubMed

13.

Teichholz LE, Kreulen T, Herman MV, Gorlin R (1976) Problems in echocardiographic volume determinations: echocardiographic angiographic correlations in the presence or absence of asynergy. Am J Cardiol 37:7–11CrossRefPubMed

14.

Schiller NB, Shah PN, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr 2:358–367CrossRefPubMed

15.

Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed

16.

Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, Asai K, Murai K, Muanakata R, Aokage T, Sakata Y, Mizuno K, Takano T (2013) ATTEND Investigators. Clinical features and outcome in hospitalized heart failure in Japan (from the ATTEND Registry). Circ J 77:944–951CrossRefPubMed

17.

Konstam MA, Kiernan M, Chandler A, Dhingra R, Mody FV, Eisen H, Haught WH, Wagoner L, Gupta D, Patten R, Gordon P, Korr K, Fileccia R, Pressler SJ, Gregory D, Wedge P, Dowling D, Romeling M, Konstam JM, Massaro JM, Udelson JE (2017) SECRTET of CHF Investigators, Coordinators, and committee members. short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 69:1409–1419CrossRefPubMed

18.

Watanabe K, Dohi K, Sugimoto T, Yamada T, Sato Y, Ichikawa K, Sugiura E, Kumagai N, Nakamori S, Nakajima H, Hoshino K, Machida H, Okamoto S, Onishi K, Nakamura M, Nobori T, Ito M (2012) Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 60:462–469CrossRefPubMed

19.

Goldsmith SR, Francis GS, Cowley AW Jr, Levine TB, Cohn JN (1983) Increased plasma arginine vasopressin levels in patients with congestive heart failure. J Am Coll Cardiol 1:1385–1390CrossRefPubMed

20.

Nakamura T, Funayama H, Yoshimura A, Tsuruya Y, Saito M, Kawakami M, Ishikawa SE (2006) Possible vascular role of increased plasma arginine vasopressin in congestive heart failure. Int J Cardiol 106:191–195CrossRefPubMed

21.

Matsukawa R, Kubota T, Okabe M, Yamamoto Y (2016) Early use of V2 receptor antagonists is associated with shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 31:1650–1658CrossRefPubMed

22.

Kiuchi S, Fujii T, Hisatake S, Kabuki T, Oka T, Dobashi S, Ikeda T (2017) Experience with long-term administration of tolvaptan to patients with acute decompensated heart failure. Drug Discov Ther 11:133–139CrossRefPubMed

23.

Kajimoto K, Abe T (2014) Blood urea nitrogen as a marker of the acute response to addition of tolvaptan to standard therapy in patients hospitalized for acute heart failure syndromes. Int J Cardio. 177:589–591CrossRef

24.

Imamura T, Kinugawa K, Shiga T, Kato N, Muraoka H, Minatsuki S, Inaba T, Maki H, Hatano M, Yao A, Kyo S, Nagai R (2013) Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients—association between non-responders and chronic kidney disease. Circ J 77:397–404CrossRefPubMed

25.

Imamura T, Kinugawa K, Komuro I (2016) Tolvaptan prolongs blockage of the vasopressin type ii receptor over 24 hours in responders with stage d heart failure. Int Heart J 57:41–46CrossRefPubMed

Title: The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients
Authors: Shunsuke Kiuchi
Shinji Hisatake
Takayuki Kabuki
Takashi Oka
Shintaro Dobashi
Takahiro Fujii
Takanori Ikeda
Publication date: 01-04-2018
Publisher: Springer Japan
Published in: Heart and Vessels / Issue 4/2018
Print ISSN: 0910-8327
Electronic ISSN: 1615-2573
DOI: https://doi.org/10.1007/s00380-017-1067-3

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Early and late outcomes after open ascending aortic surgery: 47-year experience in a single centre

Correction to: Good response to tolvaptan shortens hospitalization in patients with congestive heart failure

Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF)

Predictors of improvements in exercise capacity during cardiac rehabilitation in the recovery phase after coronary artery bypass graft surgery versus acute myocardial infarction

Impact of lesion complexity on long-term vascular response to cobalt–chromium everolimus-eluting stent: five-year follow-up optical coherence tomography study

Effects of tolvaptan on urine output in hospitalized heart failure patients with hypoalbuminemia or proteinuria

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page